Skip to main content
SpringerLink
Log in

The safety profile of the investigational adult hepatitis B vaccine Heplisav is comparable with that of the currently available Engerix-B,

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Dynavax Technologies Corporation.Dynavax Reports Positive Findings From Detailed Safety Analysis of HEPLISAV. Media Release: 23 Mar 2010. Available from: URL: http://www.dynavax.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The safety profile of the investigational adult hepatitis B vaccine Heplisav is comparable with that of the currently available Engerix-B,. React. Wkly. 1298, 2 (2010). https://doi.org/10.2165/00128415-201012980-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201012980-00005

Keywords

Search

Navigation